عرض مصدر لقاح FAKHRAVAC

{{يتيمة|تاريخ=يوليو 2021}}
{{صندوق معلومات دواء|Verifiedfields=|legal_status=|legal_BR_comment=|legal_CA=<!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->|legal_UK=<!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->|legal_US=<!-- OTC / Rx-only / Schedule I, II, III, IV, V -->|legal_UN=<!-- N I, II, III, IV / P I, II, III, IV-->|legal_NZ=<!--Class A, B, C -->|routes_of_administration=[[حقن عضلي]]
<!-- Identifiers -->|legal_AU_comment=|CAS_number=|ATCvet=|ATC_prefix=|ATC_suffix=|PubChem=|DrugBank=|legal_BR=<!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F-->|legal_AU=<!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->|verifiedrevid=|target=[[فيروس كورونا المرتبط بالمتلازمة التنفسية الحادة الشديدة النوع 2]]|drug_name=|INN=|type=vaccine|image=|alt=|caption=|vaccine_type=inactivated
<!-- Clinical data -->|pregnancy_category=|pronounce=|tradename=|Drugs.com=|MedlinePlus=|licence_EU=|licence_US=|pregnancy_AU=<!-- A/B1/B2/B3/C/D/X -->|synonyms=}}'''لقاح FAKHRAVAC''' هو [[لقاح]] مرشح ضد [[فيروس كورونا|فيروس كورونا التاسع عشر]] طورته منظمة الابتكار والبحث الدفاعي في [[إيران]]. ولم تثبت فاعليته للآن.<ref>{{استشهاد بخبر
| مؤلف1 = Motamedi, Maziar
| عنوان = Iran starts human trials of its third domestic COVID vaccine
| مسار = https://www.aljazeera.com/news/2021/3/16/iran-starts-human-trials-on-third-locally-developed-vaccine
| ناشر = Al Jazeera
| تاريخ = 16 March 2021
|مسار أرشيف= https://web.archive.org/web/20210709061729/https://www.aljazeera.com/news/2021/3/16/iran-starts-human-trials-on-third-locally-developed-vaccine|تاريخ أرشيف=2021-07-09}}</ref><ref>{{#invoke:Cite web||title=Phase 1, safety, immunogenicity and dose finding for two strengths of 0.5 × 10^6 and 2.5 × 10^6 (TCID50) inactivated SARS-CoV-2 vaccine FAKHRAVAC (MIVAC) injected in two schedules of two doses, 2 and 3 weeks apart in healthy adults aged 18-55 years: a randomized, double blind, placebo controlled, clinical trial|url=https://en.irct.ir/trial/54133|website=en.irct.ir|publisher=Iran Registry of Clinical Trials|access-date=21 March 2021|url-status=live}}</ref><ref>{{#invoke:Cite web||title=Phase 2 trial of safety and immunogenicity of 10 micro gram inactivated SARS-CoV-2 vaccine (FAKHRAVAC), two doses two weeks apart in adults aged 18-70 years: a randomized, double-blind, placebo-controlled, clinical trial|url=https://en.irct.ir/trial/56027|website=en.irct.ir|publisher=Iran Registry of Clinical Trials|access-date=15 June 2021|url-status=live}}</ref>